静脉注射羧甲基亚铁治疗不安腿综合征的临床疗效和安全性：对 537 名患者的荟萃分析

IF 3.8 2区医学 Q1 CLINICAL NEUROLOGY

Sleep medicine Pub Date : 2024-09-18 DOI:10.1016/j.sleep.2024.09.017

Syeda Nimra Qadri , Saifullah Jamil , Subhan Zahid , Tehreem Asghar , Syeda Muzna Gillani , Soban Ali Qasim , Tilyan Kambar , Zain Ul Abideen , Usama Brohi , Sammon Khan Tareen , Palay Khan Tareen , Sandhya Kumari , Satesh Kumar , Mahima Khatri

{"title":"静脉注射羧甲基亚铁治疗不安腿综合征的临床疗效和安全性：对 537 名患者的荟萃分析","authors":"Syeda Nimra Qadri , Saifullah Jamil , Subhan Zahid , Tehreem Asghar , Syeda Muzna Gillani , Soban Ali Qasim , Tilyan Kambar , Zain Ul Abideen , Usama Brohi , Sammon Khan Tareen , Palay Khan Tareen , Sandhya Kumari , Satesh Kumar , Mahima Khatri","doi":"10.1016/j.sleep.2024.09.017","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Recent research indicates that intravenous ferric carboxymaltose (IV FCM) presents a promising solution for Restless Legs Syndrome (RLS), distinguishing itself from other iron sources with minimal to no adverse effects. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety profile of administering IV FCM in patients with RLS, assuming that RLS and Iron deficiency anemia (IDA) are correlated.</div></div><div><h3>Methodology</h3><div>This study was conducted according to the PRISMA guideline, with search conducted on PubMed, Google Scholar, and the Medline library. Data was extracted from each study regarding RLS and the effect of IV FCM on it, while analysis was conducted on Review Manager Software.</div></div><div><h3>Results</h3><div>This meta-analysis comprises of 7 randomized controlled trials (RCTs). All 7 studies reported international RLS severity scale (IRLS) and the pooled analysis revealed a significant reduction in IRLS score favoring IV FCM [WMD: −6.03, 95 % CI (−10.11, −1.96), p = 0.004]. 3 out of 7 studies reported short form-36 health survey (SF-36) and the pooled analysis revealed that the total score of SF-36 significantly favors the group taking IV FCM [WMD: 7.44, 95%CI (1.67, 13.20) p = 0.01]. 4 out of 7 studies reported visual analogue scale (VAS) for RLS severity and pooled analysis revealed that IV FCM significantly decreased VAS) of RLS severity score as compared to the control [MD -19.21, 95%CI (−31.90, −6.52) p0.003].</div></div><div><h3>Conclusion</h3><div>The study findings support the efficacy of <span>IV</span> <span>FCM</span> in reducing the severity of <span>RLS</span> symptoms. Significant improvements in the IRLS scores were observed, alongside enhancements in overall quality of life measured by SF-36 scores.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"124 ","pages":"Pages 244-253"},"PeriodicalIF":3.8000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical efficacy and safety of IV ferric carboxymaltose in restless legs syndrome: A meta-analysis of 537 patients\",\"authors\":\"Syeda Nimra Qadri , Saifullah Jamil , Subhan Zahid , Tehreem Asghar , Syeda Muzna Gillani , Soban Ali Qasim , Tilyan Kambar , Zain Ul Abideen , Usama Brohi , Sammon Khan Tareen , Palay Khan Tareen , Sandhya Kumari , Satesh Kumar , Mahima Khatri\",\"doi\":\"10.1016/j.sleep.2024.09.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Recent research indicates that intravenous ferric carboxymaltose (IV FCM) presents a promising solution for Restless Legs Syndrome (RLS), distinguishing itself from other iron sources with minimal to no adverse effects. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety profile of administering IV FCM in patients with RLS, assuming that RLS and Iron deficiency anemia (IDA) are correlated.</div></div><div><h3>Methodology</h3><div>This study was conducted according to the PRISMA guideline, with search conducted on PubMed, Google Scholar, and the Medline library. Data was extracted from each study regarding RLS and the effect of IV FCM on it, while analysis was conducted on Review Manager Software.</div></div><div><h3>Results</h3><div>This meta-analysis comprises of 7 randomized controlled trials (RCTs). All 7 studies reported international RLS severity scale (IRLS) and the pooled analysis revealed a significant reduction in IRLS score favoring IV FCM [WMD: −6.03, 95 % CI (−10.11, −1.96), p = 0.004]. 3 out of 7 studies reported short form-36 health survey (SF-36) and the pooled analysis revealed that the total score of SF-36 significantly favors the group taking IV FCM [WMD: 7.44, 95%CI (1.67, 13.20) p = 0.01]. 4 out of 7 studies reported visual analogue scale (VAS) for RLS severity and pooled analysis revealed that IV FCM significantly decreased VAS) of RLS severity score as compared to the control [MD -19.21, 95%CI (−31.90, −6.52) p0.003].</div></div><div><h3>Conclusion</h3><div>The study findings support the efficacy of <span>IV</span> <span>FCM</span> in reducing the severity of <span>RLS</span> symptoms. Significant improvements in the IRLS scores were observed, alongside enhancements in overall quality of life measured by SF-36 scores.</div></div>\",\"PeriodicalId\":21874,\"journal\":{\"name\":\"Sleep medicine\",\"volume\":\"124 \",\"pages\":\"Pages 244-253\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sleep medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1389945724004386\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1389945724004386","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景最近的研究表明，静脉注射羧甲基亚铁（IV FCM）是治疗不宁腿综合症（RLS）的一种很有前景的方法，它有别于其他铁源，不良反应极小甚至没有。假定 RLS 与缺铁性贫血 (IDA) 相关，我们进行了一项系统回顾和荟萃分析，以评估静脉注射 FCM 对 RLS 患者的疗效和安全性。从每项研究中提取有关 RLS 及其静脉输注 FCM 效果的数据，并使用 Review Manager 软件进行分析。结果这项荟萃分析包括 7 项随机对照试验 (RCT)。所有 7 项研究都报告了国际 RLS 严重程度量表（IRLS），汇总分析显示，静脉输注 FCM 可显著降低 IRLS 评分[WMD：-6.03，95 % CI (-10.11, -1.96), p = 0.004]。7 项研究中有 3 项报告了短表-36 健康调查（SF-36），汇总分析表明，SF-36 总分明显有利于静脉输注 FCM 组[WMD：7.44，95%CI（1.67，13.20），p = 0.01]。7 项研究中有 4 项报告了 RLS 严重程度的视觉模拟量表（VAS），汇总分析显示，与对照组相比，静脉输注 FCM 能明显降低 RLS 严重程度的 VAS 评分[MD -19.21，95%CI (-31.90, -6.52) p0.003]。研究结果表明，IRLS 评分有明显改善，SF-36 评分衡量的整体生活质量也有所提高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical efficacy and safety of IV ferric carboxymaltose in restless legs syndrome: A meta-analysis of 537 patients

Background

Recent research indicates that intravenous ferric carboxymaltose (IV FCM) presents a promising solution for Restless Legs Syndrome (RLS), distinguishing itself from other iron sources with minimal to no adverse effects. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety profile of administering IV FCM in patients with RLS, assuming that RLS and Iron deficiency anemia (IDA) are correlated.

Methodology

This study was conducted according to the PRISMA guideline, with search conducted on PubMed, Google Scholar, and the Medline library. Data was extracted from each study regarding RLS and the effect of IV FCM on it, while analysis was conducted on Review Manager Software.

Results

This meta-analysis comprises of 7 randomized controlled trials (RCTs). All 7 studies reported international RLS severity scale (IRLS) and the pooled analysis revealed a significant reduction in IRLS score favoring IV FCM [WMD: −6.03, 95 % CI (−10.11, −1.96), p = 0.004]. 3 out of 7 studies reported short form-36 health survey (SF-36) and the pooled analysis revealed that the total score of SF-36 significantly favors the group taking IV FCM [WMD: 7.44, 95%CI (1.67, 13.20) p = 0.01]. 4 out of 7 studies reported visual analogue scale (VAS) for RLS severity and pooled analysis revealed that IV FCM significantly decreased VAS) of RLS severity score as compared to the control [MD -19.21, 95%CI (−31.90, −6.52) p0.003].

Conclusion

The study findings support the efficacy of IV FCM in reducing the severity of RLS symptoms. Significant improvements in the IRLS scores were observed, alongside enhancements in overall quality of life measured by SF-36 scores.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Sleep medicine 医学-临床神经学

CiteScore

8.40

自引率

6.20%

发文量

1060

审稿时长

49 days

期刊介绍： Sleep Medicine aims to be a journal no one involved in clinical sleep medicine can do without. A journal primarily focussing on the human aspects of sleep, integrating the various disciplines that are involved in sleep medicine: neurology, clinical neurophysiology, internal medicine (particularly pulmonology and cardiology), psychology, psychiatry, sleep technology, pediatrics, neurosurgery, otorhinolaryngology, and dentistry. The journal publishes the following types of articles: Reviews (also intended as a way to bridge the gap between basic sleep research and clinical relevance); Original Research Articles; Full-length articles; Brief communications; Controversies; Case reports; Letters to the Editor; Journal search and commentaries; Book reviews; Meeting announcements; Listing of relevant organisations plus web sites.